Literature DB >> 16565238

Chronic kidney disease as a situation of high added risk in hypertensive patients.

Julian Segura1, Jose A García-Donaire, Manuel Praga, Luis M Ruilope.   

Abstract

Recent guidelines for the management of hypertension have recognized the relevance of renal function on cardiovascular prognosis of hypertensive patients. In fact, growing evidences have confirmed that as soon as renal function exhibits minor derangements, cardiovascular risk starts a continuous rise until the development of end-stage renal disease. Both estimated glomerular filtration rate and urinary albumin excretion are associated with an increased incidence of cardiovascular events and death among hypertensive patients and in general population. Consequently, hypertensive patients presenting with chronic kidney disease are considered by guidelines as high-risk patients, and strict blood pressure control should be considered as a part of an integrative therapeutic approach, including correction of anemia, treatment of dyslipidemia, cessation of tobacco use, and antiplatelet therapy. This paper briefly reviews the most recent evidences about pharmacologic therapies in high-risk patients, focusing on benefits related to improvement of cardiovascular risk factors in hypertensive patients with chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565238     DOI: 10.1681/ASN.2005121330

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  2 in total

1.  Decreased Urinary Levels of SIRT1 as Non-Invasive Biomarker of Early Renal Damage in Hypertension.

Authors:  Olga Martinez-Arroyo; Ana Ortega; Miriam Galera; Elena Solaz; Sergio Martinez-Hervas; Josep Redon; Raquel Cortes
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

2.  Extreme Elevations in Blood Pressure and All-Cause Mortality in a Referred CKD Population: Results from the CRISIS Study.

Authors:  James Ritchie; Francesco Rainone; Darren Green; Helen Alderson; Diana Chiu; Rachel Middleton; Donal O'Donoghue; Philip A Kalra
Journal:  Int J Hypertens       Date:  2013-04-22       Impact factor: 2.420

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.